Stock Price & Analysis

The S1 support level for RGLS Stock is $1.31 ,The R1 resistant level for RGLS Stock is $1.9.

As of the end of day on 2025-04-01, the price of RGLS Stock was $1.8.

The target price for RGLS Stock according to analyst rating is 8.00, with the highest price target at 10.00 and the lowest at 6.00. Analysts have a Moderate Buy rating on RGLS Stock overall.

The market cap of RGLS is $115.9M.

Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing drugs targeting microRNAs to treat diseases. The Company is leveraging its oligonucleotide drug discovery and development to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. The Company’s lead product candidate includes RGLS8429. The Company is developing single-stranded oligonucleotides, which are chemically synthesized chains of nucleotides that are complementary to (thereby pairing with) the target microRNA. RGLS8429 is an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD). RGLS8429 maintains beneficial attributes, such as preferential kidney exposure and similar PK profile, miR-17 inhibition potency and duration of action in the kidney, equal potency in vitro and in vivo efficacy studies.

RGLS has a total of 30 employees.